Zobrazeno 1 - 10
of 210
pro vyhledávání: '"Su Xinying"'
Autor:
Su, Xinying, Chai, Weihong, Zhang, Ziyang, Tang, Zhenlin, Gao, Meihuan, Li, Yingge, Han, Zhishuang, Lv, Xinmeng, He, Jing, Li, Haidi, Zheng, Zaihang
Publikováno v:
In Applied Clay Science 15 December 2024 262
Autor:
Tang, Zhenlin, Gao, Meihuan, Li, Yingge, Su, Xinying, Zhang, Wenliang, Zheng, Zaihang, Liu, Yan
Publikováno v:
In Materials Today Communications December 2024 41
Autor:
Tang, Zhenlin, Gao, Meihuan, Li, Haidi, Zhang, Ziyang, Su, Xinying, Li, Yingge, Han, Zhishuang, Lv, Xinmeng, He, Jing, Zheng, Zaihang, Liu, Yan
Publikováno v:
In Composites Part B December 2024 287
Autor:
Han, Zhishuang, Lv, Xinmeng, Li, Yingge, Gao, Meihuan, Tang, Zhenlin, Su, Xinying, Zhang, Ziyang, Li, Haidi, He, Jing, Zheng, Zaihang, Liu, Yan
Publikováno v:
In Journal of Molecular Liquids 1 September 2024 409
Publikováno v:
In Journal of the Taiwan Institute of Chemical Engineers June 2024 159
Autor:
Zhang, Ziyang, He, Jing, Su, Xinying, Tang, Zhenlin, Gao, Meihuan, Li, Yingge, Han, Zhishuang, Lv, Xinmeng, Li, Haidi, Zheng, Zaihang, Lv, Xue
Publikováno v:
In Construction and Building Materials 23 February 2024 417
Autor:
Tang, Zhenlin, Gao, Meihuan, Zhang, Ziyang, Su, Xinying, Li, Yingge, Han, Zhishuang, Lv, Xinmeng, He, Jing, Li, Haidi, Zheng, Zaihang, Liu, Yan
Publikováno v:
In Colloids and Surfaces A: Physicochemical and Engineering Aspects 20 February 2024 683
Autor:
Yu, Lian, Li, Fei, Ni, Jie, Qin, Xianling, Lai, Junxiang, Su, Xinying, Li, Zhe, Zhang, Mengfei
Publikováno v:
In Journal of Biotechnology 10 February 2024 381:36-48
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Wu Xianhua, Zhang Jingchuan, Zhen Ruheng, Lv Jing, Zheng Li, Su Xinying, Zhu Guanshan, Gavine Paul R, Xu Songtao, Lu Shaohua, Hou Jun, Liu Yalan, Xu Chen, Tan Yunshan, Xie Liang, Yin Xiaolu, He Deming, Ji Qunsheng, Hou Yingyong, Ge Di
Publikováno v:
Journal of Translational Medicine, Vol 10, Iss 1, p 180 (2012)
Abstract Background Trastuzumab is currently approved for the clinical treatment of breast and gastric cancer patients with HER-2 positive tumors, but not yet for the treatment of esophageal carcinoma patients, whose tumors typically show 5 ~ 35% HER
Externí odkaz:
https://doaj.org/article/1c5fdd005cc242bbb013a7a8ae8560f9